Eton Pharmaceuticals, Inc. ETON Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 54.8%-3.7pp | 53.5%-6.6pp | 51.4%-7.9pp | 59.4%-0.1pp | 58.5%-7.8pp | |
| Efficiency | ||||||
| Asset turnover | 1×+0.1× | 1×+0.2× | 1×0.0× | 0.9×-0.1× | 0.8×-0.4× | |
| Inventory turnover | 2.8×+0.3× | 2.4×+0.5× | 3.6×-5.8× | 1.8×-7.0× | 2.5×-5.9× | |
| Liquidity | ||||||
| Current ratio | 1.2×-0.8× | 1.6×-0.5× | 1.6×+0.1× | 1.8×+0.4× | 2×+0.4× | |
| Quick ratio | 0.9×-0.6× | 1.2×-0.1× | 1.2×-0.2× | 1.2×-0.1× | 1.4×0.0× | |
| Cash ratio | 0.4×-0.2× | 0.7×-0.1× | 0.8×-0.2× | 0.7×-0.3× | 0.7×-0.4× | |
| Leverage | ||||||
| Debt-to-equity | 1×-0.2× | 1.2×0.0× | 1.3×+1.1× | 1.3×+0.9× | 1.2×+0.9× | |
| Debt-to-assets | 0.3×0.0× | 0.3×-0.1× | 0.3×+0.2× | 0.3×+0.1× | 0.4×+0.2× | |
| Per Share | ||||||
| Book value per share | $0.97+6.7% | —— | $0.86+42.9% | —— | $0.91+51.2% | |
| Valuation | ||||||
| Market capitalization | $930.79M+156% | $453.48M+30.7% | $582.75M+276% | $364.45M+331% | $348.09M+261% | |
| Enterprise value | $942.39M+150% | $458.63M+26.7% | $576.5M+315% | $369.77M+416% | $360.83M+326% | |
| Price / sales | 10.7×+3.2× | 5.7×-3.2× | 8.3×+3.8× | 6.3×+3.6× | 7.2×+4.4× | |
| Price / book | 30.4×+15.5× | 17.3×+3.1× | 25.2×+15.5× | 15.2×+8.9× | 14.2×+8.0× | |
| EV / sales | 10.8×+3.0× | 5.7×-3.5× | 8.2×+4.2× | 6.4×+4.1× | 7.5×+5.0× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Eton Pharmaceuticals, Inc.'s profit margins?
- Eton Pharmaceuticals, Inc. (ETON) runs a 54.8% gross margin and a -15.1% operating margin, with a -9.5% net margin.
- Where do Eton Pharmaceuticals, Inc.'s ratios come from?
- Every ratio is computed from Eton Pharmaceuticals, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
